Resumen

ESCOBAR ALVAREZ, Y.; KHOSRAVI SHAHI, P.; ENCINAS GARCIA, S.  y  IZARZUGAZA PERON, Y.. Effectivity of Cetuximab monotherapy in the treatment of refractory advanced cancer of the head and neck. An. Med. Interna (Madrid) [online]. 2008, vol.25, n.4, pp.159-162. ISSN 0212-7199.

Introduction: More than 90% of carcinoma of the head and neck (CHN) have an overexpression of the EGFR gene, and that overexpression is associated with a worse prognosis. Cetuximab is a monoclonal antibody against EGFR. Patients and methods: We have conducted a retrospective study of 10 consecutive cases with metastatic and/or recurrent CHN treated with cetuximab monotherapy as second line therapy, with the main objective of analyzing the progression-free survival (PFS); we also analyzed the response rate, the overall survival (OS), and toxicity profile as second end points. Results: The median age was 55 years, and 100% of patients were males. Fourty percent of the patients received cetuximab as second line, and 60% as third line therapy. With a median follow-up of 13.5 months, the median PFS was 4 months (95%CI: 3.4-4.6 months), with a median OS of 9.7 months (95%CI: 2.9-16.6 months).The objective response rate was 10%, and the disease control rate was 60% (Partial response = 10% and stable disease for > 16 weeks = 50%). Thirty percent of patients had grade 3 rash. Conclusions: Cetuximab monotherapy has a modest effectivity in the treatment of refractory CHN, but with a limited toxicity. Future studies should use combinations of cetuximab with others effective chemotherapeutic drugs in the treatment of CHN, such as taxanes.

Palabras clave : EGFR; Cisplatin; Cetuximab; Squamous.

        · resumen en Español     · texto en Español     · Español ( pdf )